Alnylam: Waiting For Regulatory Updates In March

Group 1 - Alnylam Pharmaceuticals (NASDAQ: ALNY) shares have remained relatively stable since the late August 2024 update, where it was indicated that the success of Amvuttra (vutrisiran) in the HELIOS-B trial for ATTR amyloidosis patients with cardiomyopathy was already reflected in the stock price [2] - The Growth Stock Forum, led by the analyst, features a model portfolio of 15-20 stocks that are regularly updated, along with a top picks list of up to 10 stocks expected to perform well in the current calendar year [2] Group 2 - The article emphasizes that past performance is not indicative of future results, and no specific investment recommendations are provided [4]